Edition:
United Kingdom

Medigene AG (MDG1k.DE)

MDG1k.DE on Xetra

11.10EUR
16 Oct 2018
Change (% chg)

-- (--)
Prev Close
€11.10
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
171,033
52-wk High
€19.42
52-wk Low
€9.86

Summary

Name Age Since Current Position

Horst Domdey

66 2013 Chairman of the Supervisory Board

Dolores Schendel

2016 Chairman of the Executive Management Board, Chief Executive Officer, Chief Scientific Officer

Antoinette Hiebeler-Hasner

59 2016 Deputy Chairman of the Supervisory Board

Markus Dangl

2016 Senior Vice President Research & Pre-Clinical Development

Olav Zilian

2016 Senior Vice President Corporate Development

Kai Pinkernell

2018 Member of the Executive Management Board, Chief Medical Officer, Chief Development Officer

Yita Lee

46 2013 Member of the Supervisory Board

Keith Manchester

49 2017 Member of the Supervisory Board

Ronald Scott

62 2017 Member of the Supervisory Board

Gerd Zettlmeissl

62 2017 Member of the Supervisory Board

Julia Hofmann

Investor & Public Relations Contact Officer
» Insider Trading

Biographies

Name Description

Horst Domdey

Prof. Dr. Horst Domdey has been Chairman of the Supervisory Board at Medigene AG since July 16, 2013. He is a co-founder of Medigene AG and Managing Director of BioM Biotech Cluster Development GmbH and Management Board Member of BioM AG Munich Biotech Development, Munich, Germany.

Dolores Schendel

Prof. Dr. Dolores J. Schendel has been Chairman of the Executive Management Board, Chief Executive Officer and Chief Scientific Officer at MediGene AG since February 1, 2016. Previously she served as Chief Scientific Officer and Member of Executive Board of the Company from May 1, 2014. She has served as Director of the Institute of Molecular Immunology at the Helmholtz-Zentrum München and Managing Director of Trianta Immunotherapies GmbH.

Antoinette Hiebeler-Hasner

Ms. Antoinette Hiebeler-Hasner has been Deputy Chairman of the Supervisory Board at Medigene AG since August 11, 2016. She is Member of the Compensation and Nomination Committee and Chairman of the Audit Committee at the Company. She has been Chairperson of the Supervisory Board of Grob Aircraft AG, Member of the Supervisory Board of Ventuz Technology AG, Partner of Vistra GmbH & Co. KG Wirtschaftspruefungsgesellschaft and Managing Director of Wilder Kaiser GmbH Steuerberatungsgesellschaft (Tax Consultants).

Markus Dangl

Dr. Markus Dangl has been Senior Vice President Research & Pre-Clinical Development at Medigene AG since March 2016. Dr. Dangl held positions at Roche in the past 14 years, including the establishment of the Roche Translational Medicine Hub in Singapore where he was responsible for all research and translational medicine activities. Most recently he worked as Department Head DTA Oncology and Preclinical Science Leader MDM2 Franchise, Pharma Research and Early Development, Roche Diagnostics GmbH. He studied biochemistry and received a Ph.D. in biochemistry from the Leopold-Franzens University of Innsbruck, Austria.

Olav Zilian

Dr. Olav Zilian has been Senior Vice President Corporate Development at Medigene AG since January 2016. Dr. Zilian can look back on experience in brokerage service, investment banking and consultancy from his past eleven years at the Swiss based Baader Bank subsidiary Helvea SA where he focused as Senior Analyst on sell-side research for European healthcare companies. Prior to that, he worked as Research Assistant Professor at the Swiss Institute for Experimental Cancer Research (ISREC) where he headed and integrated a team of 12 collaborators at the interface of fundamental and applied research. Previously, he was a Postdoctoral Research Fellow in the Department of Molecular Oncology at Genentech Inc. in San Francisco. Dr. Zilian studied medicine and holds a MD from the University of Basel, Switzerland and a Ph.D. in molecular biology from the University of Zurich, Switzerland. He has received several awards for his analyst work, e.g. as "Europe No. 1 Stock Picker in Biotechnology" in 2014, and recently received an Executive Master of Business Administration from the International Institute for Management Development (IMD), Lausanne, Switzerland.

Kai Pinkernell

Dr. Kai Pinkernell has been Member of the Executive Management Board, Chief Medical Officer and Chief Development Officer of Medigene AG since April 11, 2018. He was Senior Vice President/Chief Medical Officer at Medigene AG from February 2016. He is responsible for the clinical development, regulatory affairs and manufacturing of Medigene's products. He has 17 years of experience in global clinical development of cell therapies including preclinical activities, the automation and GMP production as well as in commercialization and business development activities. Before joining Medigene, he held various management positions at Miltenyi Biotech GmbH, Bergisch Gladbach, Germany, most recently as Global Head of Clinical Business and Head of Clinical Development. Before that, Dr. Pinkernell served as Senior Director of Regenerative Cell Technology for Cytori Therapeutics Inc. of San Diego, USA. He studied medicine and obtained his doctorate at the Westfaelische Wilhelms-University Muenster. In addition, Dr. Pinkernell holds a Master of Business Administration from the Marshall School of Business, University of Southern California, Los Angeles, USA.

Yita Lee

Dr. Yita Lee has been Member of the Supervisory Board at Medigene AG since July 16, 2013. He is Chairman of the Compensation and Nomination Committee and Member the Audit Committee at the Company. Dr. Lee is Chief Scientific Officer of the Sinphar Group, Taipei, Taiwan. He has been Member of the Board of Directors of Sinphar Pharmaceutical Co., Ltd., Member of the Board of Directors of SynCore Biotechnology Co., Ltd., Member of the Board of Directors of ZuniMed Biotech Co., Ltd. and Member of the Board of Directors of CanCap Pharmaceutical Ltd.

Keith Manchester

Dr. Keith Manchester has been Member of the Supervisory Board at Medigene AG since May 24, 2017. He serves as Managing Director and the Head of Life Sciences at QVT Financial LP, New York, an investment firm, where he has been employed since 2005. He focuses on investments in both publicly traded and privately owned life sciences companies. Dr. Manchester also serves as Director of Arbutus Biopharma Corporation, Myovant Sciences Ltd. and Roivant Sciences, Inc. Prior to joining QVT, Dr. Manchester was Vice President of Business Development from 2002 to 2004 and Director of Business Development from 2000 to 2002 at Applied Molecular Evolution, Inc., a biotechnology company. From 1999 to 2000, Dr. Manchester was an associate at Vestar Capital Partners, a private equity firm. From 1997 to 1999, Dr. Manchester was an investment banker in the healthcare group at Goldman, Sachs & Co. Dr. Manchester received his AB degree from Harvard College and his M.D. degree from Harvard Medical School.

Ronald Scott

Mr. Ronald Scott has been Member of the Supervisory Board at Medigene AG since May 24, 2017. He has served at Basilea Pharmaceutical International Ltd., Basel, Switzerland, as Chief Executive Officer since January 2013. He was Basilea's Chief Operating Officer from January through December 2012, and served as Basilea's Chief Financial Officer from the Company’s founding in 2000 through January 2012 as well as ad interim Chief Financial Officer from February 2013 until November 2013. From 2004 to October 2011, Mr. Scott served on the Board of Directors and was a co-founding Board member in 2000. Prior to joining Basilea, Mr. Scott worked at Roche Holding AG (Roche) in management positions in Pharmaceutical Finance, Licensing, and the Roche Corporate Finance Mergers and Acquisitions group. Prior to joining Roche, Mr. Scott worked for Prudential Investment Corporation in the United States as Director in Prudential’s Finance and International Business Development Units, managing divestitures and joint venture transactions. Mr. Scott has a Bachelor’s degree from Utah State University and a Master’s degree from Harvard University.

Gerd Zettlmeissl

Dr. Gerd Zettlmeissl has been Member of the Supervisory Board at Medigene AG since May 24, 2017. He has more than 25 years of scientific and leadership experience in the biopharmaceutical industry. He currently serves as representative of the Board of Directors of several non-profit organizations and biotech companies. Until early 2015 he was Chairman of GlycoVaxyn (Switzerland), a vaccine company acquired by GlaxoSmithKline. He is the former Chief Executive Officer of the Austrian-based biotechnology company Intercell AG (now Valneva SE). While at Intercell AG from 2001 to 2011, he built the company from a private start-up venture to a publicly listed international organization with more than 400 employees. As Chief Executive Officer, he secured global regulatory approval for and led the launch of an improved Japanese Encephalitis vaccine, and oversaw efforts to build and advance a broad based development portfolio of vaccines. Prior to joining Intercell, Dr. Zettlmeissl was Managing Director of Chiron Behring GmbH and held senior management roles in biopharmaceutical R&D and Technical Operations at Chiron Corp. and Behringwerke AG. In 2010, he was named Vaccine Biotech Chief Executive Officer of the Year at the World Vaccine Congress. Dr. Zettlmeissl holds a doctoral degree in biochemistry of the University of Regensburg and did a post- doctoral fellowship at the Institut Pasteur Paris in virology.

Julia Hofmann

Insider Trading

» Full list on Insider Trading